NCT07600515|Not Yet Recruiting
Evaluation of Persistent Infection by Oncogenic Human Papillomavirus (HPV) in Patients Treated for Cervical Carcinoma and Its Relation to Prognostic Factors
ANIHTA
Loading search results
ANIHTA
Sponsor study identifier
observational
100
0 countries
N/A
Study Start
May 10, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
May 10, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
May 10, 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Cervical cancer is strongly associated with HPV infection, yet current post-treatment follow-up relies on cytology and imaging, which have limited accuracy, particularly after radiotherapy. Emerging evidence suggests that HPV clearance is linked to better outcomes and that HPV testing may outperform cytology in detecting recurrence. This study aims to evaluate a panel of prognostic biomarkers to identify patients at higher risk of recurrence. These include cervical and circulating HPV-DNA (presence, genotype, and load), vaginal microbiota, host DNA methylation, SOD2 expression, and immune profile. By enabling earlier and more accurate detection of recurrence, these biomarkers may improve patient outcomes, reduce reliance on costly imaging, and support earlier discharge for low-risk patients.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
May 10, 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 10, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
May 14, 2026
Actual (reported)May 20, 2026
Actual (reported)May 10, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
May 10, 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
recurrence after curative-intent treatment
evaluate the relationship between the occurrence of recurrences after curative-intent treatment and the persistence of HPV infection
18 months
cervical cancer HPV positive
Patients referred to ICESP
blood cervical sample
First Submitted
May 14, 2026
First Posted
May 20, 2026
Study Start
May 10, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
May 10, 2029
EstimatedIparomlimab/Tuvonralimab Combined With Nab-paclitaxel and Cisplatin as Neoadjuvant Therapy for Locally Advanced Cervical Cancer
Contact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
May 10, 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
June 3, 2026
Record last verified: 2026-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: